Respiratory Medicine and Research最新文献

{"title":"Safety of non-cuffed tunneled central venous catheters in adults with cystic fibrosis","authors":"Arshan Dehbozorgi ,&nbsp;Badr Jandali ,&nbsp;Robert Turner ,&nbsp;Aaron Rohr ,&nbsp;Brandon Custer ,&nbsp;Kate Young ,&nbsp;Carissa Walter ,&nbsp;Lauren Clark ,&nbsp;Yanming Li ,&nbsp;Deepika Polineni ,&nbsp;Joel Mermis","doi":"10.1016/j.resmer.2023.101073","DOIUrl":"10.1016/j.resmer.2023.101073","url":null,"abstract":"<div><h3>Background</h3><p>Peripherally inserted central catheters (PICCs) are the most common route of intravenous (I.V.) access for treatment of cystic fibrosis (CF) pulmonary exacerbations, but repeated PICC placement can result in upper extremity peripheral venous stenosis. Once peripheral stenosis develops, a non-cuffed tunneled central venous catheter (NcTCVC) is an alternative route for IV access. While these are regularly used at some CF centers, the safety and complication rate compared to PICCs in adults with CF has not been reported. This study aims to describe the safety of NcTCVCs in adults with CF.</p></div><div><h3>Methods</h3><p>A retrospective cohort study was performed at a CF Foundation accredited institution including adults with CF who received NcTCVCs in interventional radiology from 7/19/2007 to 3/09/2020. Complications analyzed included catheter related deep venous thrombosis (DVT), central line associated blood stream infection (CLABSI), and catheter related central venous stenosis. Complications were considered attributable if they occurred while the catheter was in place or within 30 days of catheter removal.</p></div><div><h3>Results</h3><p>During the study duration, 386 NcTCVCs were placed in 60 unique patients (55 % female) with a mean of 6.4 catheters per patient. Majority of NcTCVCs placed were 4 French (61.4 %). Average duration of indwelling NcTCVC was 16.2 days. No patients demonstrated catheter attributable symptomatic DVT. The incidence of DVT, CLABSI, and central venous stenosis was 0 (0 %), 4 (1 %), and 1 (0.3 %), respectively.</p></div><div><h3>Conclusions</h3><p>Many adults with CF have required insertion of numerous PICCs for the treatment of recurrent pulmonary exacerbations. In those adults that develop PICC-associated peripheral vein stenosis precluding PICC placement, these results indicate NcTCVCs are a safe alternative.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101073"},"PeriodicalIF":2.3,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041223000855/pdfft?md5=4ca6b4ec9bb6e7de247329c33407007a&pid=1-s2.0-S2590041223000855-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Onset of eosinophilic granulomatosis with polyangiitis (EGPA) after anti-Th2 biotherapy initiation in severe asthma patients: Report of 3 cases","authors":"Marine Fargeas ,&nbsp;Gilles Devouassoux ,&nbsp;Mathieu Gerfaud-Valentin","doi":"10.1016/j.resmer.2023.101070","DOIUrl":"10.1016/j.resmer.2023.101070","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101070"},"PeriodicalIF":2.3,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139032786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary function test results are correlated with 6-minute walk distance, distance-saturation product, and 6-minute walk work in patients with lymphangioleiomyomatosis","authors":"Rémi Diesler ,&nbsp;Vincent Cottin ,&nbsp;Yves Gallien ,&nbsp;Ségolène Turquier ,&nbsp;Julie Traclet ,&nbsp;Kais Ahmad ,&nbsp;Jean-Charles Glerant","doi":"10.1016/j.resmer.2023.101071","DOIUrl":"10.1016/j.resmer.2023.101071","url":null,"abstract":"<div><h3>Background and objective</h3><p><span>Lymphangioleiomyomatosis<span><span> (LAM) is a rare multicystic lung disease. Although a correlation between </span>pulmonary function test (PFT) results and exercise capacity appears probable, it has not yet been demonstrated. The aim of this study was to assess whether PFT results correlate with 6-minute walk test (6MWT) results </span></span>in patients with LAM.</p></div><div><h3>Methods</h3><p>We conducted a retrospective study of all patients with a diagnosis of LAM followed in a French reference centre over a 13-year period. PFT and 6MWT data were collected. Distance-saturation product (DSP) and 6-minute walk work (6MWORK) were calculated.</p></div><div><h3>Results</h3><p><span><span>A total of 62 patients were included. Their median forced expiratory volume in 1 s (FEV1) was 82.7 % predicted and their median </span>forced vital capacity<span> (FVC) was 96.7 % predicted. The median diffusing capacity<span> of the lungs for carbon monoxide (DLCO) was 58.5 % predicted and was decreased in 79 % of the patients. The median 6-minute walk distance was 535 m, which was 90.9 % of the 602 m predicted distance. The median DSP was 497.4 m % and the median 6MWORK was 32,910 kg.m. The distance walked during the 6MWT was significantly correlated with FVC%predicted (</span></span></span><em>R</em> = 0.435), FEV1 %predicted (<em>R</em> = 0.303), TLC%predicted (<em>R</em> = 0.345), FRC%predicted (<em>R</em> = 0.262), RV/TLC ratio (<em>R</em> = -0.271), and DLCO%predicted (<em>R</em> = 0.279). DSP and 6MWORK were each significantly correlated with different PFT results.</p></div><div><h3>Conclusion</h3><p>The present study shows that PFT results are potential predictors of the exercise capacity in patients with LAM. Additional studies are required to evaluate the interest of DSP and 6MWORK in LAM.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101071"},"PeriodicalIF":2.3,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139032787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab-induced rhinitis in severe asthma patients: A case series","authors":"Goël Fenech,&nbsp;Muriel Hourseau,&nbsp;Jean-Pierre Cristofari,&nbsp;Clairelyne Dupin,&nbsp;Camille Taillé","doi":"10.1016/j.resmer.2023.101072","DOIUrl":"10.1016/j.resmer.2023.101072","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101072"},"PeriodicalIF":2.3,"publicationDate":"2023-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138886268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Behaviour change interventions for physical activity in adults with chronic obstructive pulmonary disease; A systematic review and meta-analysis","authors":"Ciara Hanrahan ,&nbsp;Julie Broderick ,&nbsp;Terence M. O'Connor ,&nbsp;Joseph G. McVeigh","doi":"10.1016/j.resmer.2023.101068","DOIUrl":"10.1016/j.resmer.2023.101068","url":null,"abstract":"<div><h3>Background</h3><p><span>Physical activity in adults with COPD is poor, but behaviour change interventions could help improve activity. This </span>systematic review aims to examine behaviour change interventions to promote physical activity and health outcomes for adults with COPD.</p></div><div><h3>Methods</h3><p>Eight databases were searched from inception until April 2023: Web of Science, CENTRAL, MEDLINE, EMBASE, APA PsychINFO, CINAHL, PROSPERO, Cochrane Airways Trials Register. Relevant studies were appraised to determine the impact of behaviour change interventions on physical activity outcomes. Interventions were mapped to Michie's Theoretical Domains Framework (TDF) and a meta-analysis and narrative synthesis conducted. The Cochrane risk of bias tool 2 and the GRADE criteria evaluated bias and the quality and certainty of the evidence.</p></div><div><h3>Results</h3><p><span>Twelve randomized controlled trials (RCTs) were included in the review (</span><em>n</em><span><span> = 1211). The most frequently utilized behaviour change interventions included counselling, stepcount monitoring, social support and goal setting. The most commonly measured outcomes across studies were steps-per-day, physical activity levels, exercise capacity and </span>quality of life. A meta-analysis of comparable studies demonstrated there was no difference in stepcount in favour of behaviour change interventions with respect to steps-per-day (SMD 0.16, 95 % CI -0.03, 0.36; </span><em>p</em> = 0.10). There was some evidence of short-term improvement in physical activity and quality of life, with behaviour change interventions related to goals, behaviour regulation and social influences.</p></div><div><h3>Conclusions</h3><p>People with COPD may benefit from behaviour change interventions to increase physical activity and quality of life in the short-term. The overall certainty and quality of the evidence is low.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101068"},"PeriodicalIF":2.3,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135763487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous thromboembolism in sarcoidosis: Mere comorbidity or catalyst for disease evolution?","authors":"Mitja Jevnikar,&nbsp;Géraldine Poenou,&nbsp;David Montani,&nbsp;Laurent Bertoletti","doi":"10.1016/j.resmer.2023.101062","DOIUrl":"10.1016/j.resmer.2023.101062","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101062"},"PeriodicalIF":2.3,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135456160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"U-net convolutional neural network applied to progressive fibrotic interstitial lung disease: Is progression at CT scan associated with a clinical outcome?","authors":"Xavier Guerra ,&nbsp;Simon Rennotte ,&nbsp;Catalin Fetita ,&nbsp;Marouane Boubaya ,&nbsp;Marie-Pierre Debray ,&nbsp;Dominique Israël-Biet ,&nbsp;Jean-François Bernaudin ,&nbsp;Dominique Valeyre ,&nbsp;Jacques Cadranel ,&nbsp;Jean-Marc Naccache ,&nbsp;Hilario Nunes ,&nbsp;Pierre-Yves Brillet","doi":"10.1016/j.resmer.2023.101058","DOIUrl":"10.1016/j.resmer.2023.101058","url":null,"abstract":"<div><h3>Background</h3><p>Computational advances in artificial intelligence have led to the recent emergence of U-Net convolutional neural networks (CNNs) applied to medical imaging. Our objectives were to assess the progression of fibrotic interstitial lung disease (ILD) using routine CT scans processed by a U-Net CNN developed by our research team, and to identify a progression threshold indicative of poor prognosis.</p></div><div><h3>Methods</h3><p>CT scans and clinical history of 32 patients with idiopathic fibrotic ILDs were retrospectively reviewed. Successive CT scans were processed by the U-Net CNN and ILD quantification was obtained. Correlation between ILD and FVC changes was assessed. ROC curve was used to define a threshold of ILD progression rate (PR) to predict poor prognostic (mortality or lung transplantation). The PR threshold was used to compare the cohort survival with Kaplan Mayer curves and log-rank test.</p></div><div><h3>Results</h3><p>The follow-up was 3.8 ± 1.5 years encompassing 105 CT scans, with 3.3 ± 1.1 CT scans per patient. A significant correlation between ILD and FVC changes was obtained (<em>p</em> = 0.004, ρ = -0.30 [95% CI: -0.16 to -0.45]). Sixteen patients (50%) experienced unfavorable outcome including 13 deaths and 3 lung transplantations. ROC curve analysis showed an aera under curve of 0.83 (<em>p</em> &lt; 0.001), with an optimal cut-off PR value of 4%/year. Patients exhibiting a PR ≥ 4%/year during the first two years had a poorer prognosis (<em>p</em> = 0.001).</p></div><div><h3>Conclusions</h3><p>Applying a U-Net CNN to routine CT scan allowed identifying patients with a rapid progression and unfavorable outcome.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101058"},"PeriodicalIF":2.3,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135371043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics, management, and healthcare resources of patients with advanced non–small-cell lung cancer surviving 5 years after nivolumab treatment initiation: A national database analysis","authors":"Jean-Baptiste Assié ,&nbsp;Valentine Grumberg ,&nbsp;Dorothée Reynaud ,&nbsp;Anne-Françoise Gaudin ,&nbsp;Alexandre Batisse ,&nbsp;Ronan Jolivel ,&nbsp;Baptiste Jouaneton ,&nbsp;François-Emery Cotté ,&nbsp;Christos Chouaïd","doi":"10.1016/j.resmer.2023.101051","DOIUrl":"10.1016/j.resmer.2023.101051","url":null,"abstract":"<div><h3>Background</h3><p>Data on long-term survivors with advanced non-small-cell lung cancer (NSCLC) treated with nivolumab are available from randomized trials. Characteristics, management, and healthcare resources of those patients need to be confirmed with real-world data.</p></div><div><h3>Methods</h3><p>The UNIVOC retrospective observational study included all patients with advanced NSCLC recorded in the French national hospital database starting nivolumab in 2015 and followed them until December 2020. The Kaplan-Meier method estimated the overall survival (OS). A machine learning approach identified patients with similar treatment sequences.</p></div><div><h3>Results</h3><p>Within the 3,050 patients who had nivolumab initiation,5-year OS rate was 14.6 % (95 %CI 13.3 %–16.2 %). In total, data covering at least 5 years of follow-up were retrieved for 231 surviving patients. Survivors were younger, often female and had fewer comorbidities than non-survivors. Three clusters of patients with different nivolumab treatment durations were identified: 1/ Continuous nivolumab treatment; 2/ Long period of nivolumab treatment followed by chemotherapy or no treatment; 3/ Short period of nivolumab treatment then chemotherapy or no treatment. At 5 years, 61.0 % of survivors were no longer receiving systemic therapy, 26.4 % were treated with nivolumab, 8.7 % chemotherapy, and 3.9 % other immunotherapies. Among 5-y survivor patients, the average number of hospitalisations per patient decreased from 23.4 to 12.8 between the 1st and the 5th year. In the 5th year, 46 % of patients had no more hospitalization for lung cancer.</p></div><div><h3>Conclusions</h3><p>This large nationwide study confirms the long-term benefit of nivolumab treatment for advanced NSCLC patients in the real-world setting, with a 5-year survival rate similar to that reported in clinical trials.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101051"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041223000636/pdfft?md5=59c8da3e00597bad7c492a390564d1dc&pid=1-s2.0-S2590041223000636-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66784497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical activity and sedentary behaviour in patients admitted with COPD: Associated factors","authors":"Cristóbal Esteban ,&nbsp;Ane Antón-Ladislao ,&nbsp;Amaia Aramburu ,&nbsp;Leyre Chasco ,&nbsp;Miren Orive ,&nbsp;Patricia Sobradillo ,&nbsp;Lorena López-Roldan ,&nbsp;Alberto Jiménez-Puente ,&nbsp;Javier de Miguel ,&nbsp;Ignacio García-Talavera ,&nbsp;José M. Quintana ,&nbsp;the ReEPOC-REDISSEC group","doi":"10.1016/j.resmer.2023.101052","DOIUrl":"10.1016/j.resmer.2023.101052","url":null,"abstract":"<div><h3>Aim</h3><p>To establish amongst a cohort of patients admitted with Chronic Obstructive Pulmonary Disease which factors were associated with their level of Physical Activity and Sedentary Behavior prior to the admission event.</p></div><div><h3>Methods</h3><p><span>Prospective observational cohort study. Nine Spanish hospitals participated. Patients were recruited consecutively. Variables relating to the patients' clinical baseline status were recorded, including the COPD Assessment test, the HADS anxiety-depression test, comorbidities and the Yale Physical Activity Survey. Data relating to admission and up to two months </span>after discharge were also recorded.</p></div><div><h3>Results</h3><p><span>1638 COPD patients were studied, with a mean age of 72.39 (SD 10.33), 76.56 % male, FEV1<span> 49.41 % (SD19.19), Charlson index 2. The level of PA at baseline was 30.79 points (SD 22.43). Multivariable </span></span>linear regression analysis<span><span> identified the following as being associated with low PA: older age, obesity, higher level of hemoglobin, lower score of Barthel index, which means disability, health related </span>quality of life (EuroQoL-5d and CAT) and dyspnea. Variables associated with sedentary behavior were: older age, presence of obstructive apnea syndrome, higher disability, presence of depressive symptoms and dyspnea.</span></p></div><div><h3>Conclusions</h3><p>In a cohort of hospitalized COPD patients, we have found several variables, some of them modifiable, associated with physical activity/inactivity and sedentary behavior.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101052"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66784498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary arterial hypertension and COVID-19: Piecing the puzzle","authors":"Fida Charif ,&nbsp;Fatima Dakroub ,&nbsp;Imad Bou Akl ,&nbsp;Mithum Kularatne ,&nbsp;David Montani","doi":"10.1016/j.resmer.2023.101053","DOIUrl":"https://doi.org/10.1016/j.resmer.2023.101053","url":null,"abstract":"<div><p><span><span>COVID-19 remains a health care concern despite the end of the pandemic. Patients with cardiovascular disease (CVD) are at a higher risk for developing severe COVID-19 complications. Studies investigating the COVID-19 clinical characteristics in pulmonary arterial hypertension (PAH) patients have reported discordant conclusions so far. In this review, we summarize the literature pertaining to the clinical presentation of COVID-19 </span>in patients<span> with PAH. In addition, we discuss common pathological aspects and disease mechanisms between PAH and COVID-19. We present an overview of the different types of PAH-approved therapy and their potential utilization as a treatment in the context of COVID-19. Moreover, we summarize the </span></span>clinical trials<span> that assessed the safety and efficiency of PAH-approved drugs in COVID-19 patients. Finally, we conclude with proposals for prospective research studies.</span></p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101053"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91956662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}